• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Allergan

Medtronic taps Lennon as CIO | Personnel Moves – April 9, 2018

April 9, 2019 By Fink Densford

Medtronic (NYSE:MDT) said that it named Sean Lennon as its new chief information officer, set to take effect April 29. The Fridley, Minn.-based medtech giant said that Lennon will take over for Mike Hedges, who is retiring from the position after 19 years with Medtronic, including 10 as CIO. Prior to joining Medtronic, Lennon served as […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: Allergan, Clearside Biomedical, ICU Medical Inc., iHear Medical, LifeScan Inc., lumenxt, Medtronic, Novartis, OptiScan, oregonbioscienceassociation, Owens and Minor, Shape Memory Therapeutics, SynCardia

Health Canada notifies Allergan on intent to suspend Biocell breast implant license

April 5, 2019 By Fink Densford

Health Canada said yesterday that it plans to suspend Allergan‘s (NYSE: AGN) licenses to sell its Biocell breast implants in the region due to a possible association with a rare immune system-cancer. The move follows the agency’s completion of a scientific assessment of macro-textured implants, which it said is part of a larger safety review of […]

Filed Under: Business/Financial News, Cosmetic/Aesthetic, Regulatory/Compliance, Women's Health Tagged With: Allergan

Number of cancer cases linked to breast implants soars

February 7, 2019 By Nancy Crotti

FDA said it has received reports of 457 unique cancer cases related to breast implants since 2010, including nine patient deaths. The agency identified those unique cases from a total of 660 adverse event reports in the U.S. from 2010 through September 2018, including 246 new adverse event reports since 2017. FDA began reporting on cases […]

Filed Under: Featured, Food & Drug Administration (FDA), Implants, News Well, Oncology, Women's Health Tagged With: Allergan, Center for Devices and Radiological Health (CDRH), FDA

Report: Pharma companies kick off new year with price hikes

January 2, 2019 By Sarah Faulkner

Major pharmaceutical firms started the new year by hiking the prices of hundreds of drugs, according to a new study published by Rx Savings Solutions. First reported in The Wall Street Journal, the study found that the average price increase taken by more than three dozen companies was roughly 6.3%. Get the full story at our […]

Filed Under: Business/Financial News, Pharmaceutical, Wall Street Beat Tagged With: Allergan, Biogen, Bristol-Myers Squibb Co., Eli Lilly & Co., Pfizer

Report: Despite settlement, patient seeks prosecution for off-label Seri scaffold breast surgery

December 21, 2018 By Fink Densford

A patient in Southern California who underwent breast reconstruction surgery using an off-label Seri surgical scaffold is pushing for the state to prosecute the operating plastic surgeon, despite having received $1 million in a settlement, over claims that he altered her medical records, according to a Pasadena Star News report. The patient, Wendy Knecht, underwent […]

Filed Under: Cosmetic/Aesthetic, Legal News, Women's Health Tagged With: Allergan, Serica Technologies, Sofregen Medical

Allergan pulls textured breast implants from the European market

December 19, 2018 By Sarah Faulkner

Allergan (NYSE: AGN) has removed its textured breast implants from the market in Europe following a recall request from French regulators. France’s National Agency for the Safety of Medicines and Health Products said that it hasn’t “identified any immediate risk for the health of women carrying the implants,” and that it plans to convene an expert committee […]

Filed Under: Implants, Recalls, Regulatory/Compliance, Wall Street Beat, Women's Health Tagged With: Allergan

FDA approves five-year hormonal contraceptive

October 16, 2018 By Sarah Faulkner

Allergan (NYSE:AGN) and the nonprofit women’s health pharma company Medicines360 said today that the FDA approved an application to extend the duration of use for Liletta for the prevention of pregnancy for up to five years. Medicines360 first won approval for the levonorgestrel-releasing intrauterine device in February of 2015. The system’s latest FDA approval is based on a […]

Filed Under: Clinical Trials, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Allergan, Medicines360

FDA pushes back on silicone breast implant study

September 17, 2018 By Brad Perriello

The FDA last week pushed back at a large study showing an association between silicone breast implants and some rare diseases, standing by its record of warning the public about their risks – despite granting approvals to a slew of the implants in recent years. The study, published Sept. 14 in the Annals of Surgery, […]

Filed Under: Featured, Food & Drug Administration (FDA), Women's Health Tagged With: Allergan, Johnson and Johnson

Oyster Point takes aim at the root of dry eye disease with intranasal drug-delivery technique

July 12, 2018 By Sarah Faulkner

Large pharmaceutical companies dominate the dry eye disease space – Allergan (NYSE:AGN) rakes in more than a billion dollars every year for its Restasis eye drops. Eight-person Oyster Point Pharma wants in on that market. But it’s betting on a completely different approach. “What we’ve come up with is a very innovative nasal spray, which when sprayed into the […]

Filed Under: Clinical Trials, Drug-Device Combinations, Optical/Ophthalmic, Pharmaceutical Tagged With: Allergan, oysterpointpharma

Tribe taking steps to ‘ramp up’ drug patent business

May 22, 2018 By Sarah Faulkner

The Native American tribe wrapped up in litigation with generic pharmaceutical companies is trying to prove that its arrangement with Allergan (NYSE:AGN) reflects a legitimate move to boost its economy, according to court documents. The St. Regis Mohawk Tribe of New York found itself it the middle of a controversial deal this year after it agreed to […]

Filed Under: Legal News, Pharmaceutical, Wall Street Beat Tagged With: Allergan, Mylan

Allergan touts 5-year data for Liletta intrauterine contraceptive

May 1, 2018 By Sarah Faulkner

Allergan (NYSE:AGN) and its nonprofit partner, Medicines360, touted five-year data today from an on-going pivotal trial of its intrauterine device, Liletta. The levonorgestrel-releasing contraceptive is approved in the U.S. to be used to prevent pregnancy for up to four years. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Wall Street Beat, Women's Health Tagged With: Allergan, Medicines360

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 25
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS